热门资讯> 正文

Cellectar Biosciences reports FY results

2025-03-13 19:23

Cellectar Biosciences press release (NASDAQ:CLRB): FY Net loss for the full year ending December 31, 2024, was $44.6 million or $1.22 per basic share and $1.40 per diluted share, compared with $42.8 million or $3.50 per basic and diluted share during 2023.
As of December 31, 2024, the company had cash and cash equivalents of $23.3 million, compared to $9.6 million as of December 31, 2023.

More on Cellectar Biosciences

Micron Technology, Nike Lead Companies That Report As Earnings Season Continues To Slow
Seeking Alpha’s Quant Rating on Cellectar Biosciences
Historical earnings data for Cellectar Biosciences
Financial information for Cellectar Biosciences

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。